Trial register facet
Trial records reported in 2019 — page 2
37 records with a recorded report or completion year of 2019.
Showing 0 records on this page
Records
37 documents · page 2 of 2
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| RECONNECT-302-HEPATIC-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-302-PKprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| RECONNECT-302-RENAL-IMPprogramme record | PT-141 (bremelanotide) | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| REWIND | Dulaglutide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,901 | 2019 | High |
| REWIND-BIOMARKERprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| REWIND-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| TESA-NAFLD-PH2 | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 61 | 2019 | Low |
| TESA-NAFLD-PH2-BODY-COMPprogramme record | Tesamorelin | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| TESA-NAFLD-PH2-HEPATIC-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| TESA-NAFLD-PH2-PKprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
| TESA-NAFLD-PH2-RENAL-IMPprogramme record | Tesamorelin | Phase 1 | Reported | Phase 1 ascending dose | — | 2019 | Very low |
page 2 of 2